National Engineering Research Center of Edible Fungi, Key Laboratory of Applied Mycological Resources and Utilization, Ministry of Agriculture, Shanghai Key Laboratory of Agricultural Genetics and Breeding, Institute of Edible Fungi, Shanghai Academy of Agriculture Science, Shanghai, 201403, People's Republic of China.
College of Food Science, Shanghai Ocean University, Shanghai, 201306, People's Republic of China.
Sci Rep. 2019 Apr 9;9(1):5818. doi: 10.1038/s41598-019-42104-1.
Fungal immunoregulatory proteins (FIP) are effective small molecule proteins with broad-spectrum immunomodulatory and anti-cancer activities and can be potential agents for the development of clinical drugs and health food additives. In this study, a new member of FIP named FIP-bbo was obtained through Botryobasidium botryosum genome mining. FIP-bbo has the typical characteristics of FIP but is genetically distant from other FIPs. Recombinant FIP-bbo (rFIP-bbo) was produced in an optimized E. coli expression system, and the pure protein was isolated using a Ni-NTA column. Antineoplastic experiments suggested that FIP-bbo is similar to LZ-8 in inhibiting various cancer cells (Hela, Spac-1, and A549) at lower concentrations, but it is not as potent as LZ-8. The molecular mechanism by which FIP-bbo, FIP-fve, and LZ-8 are cytotoxic to cancer cells has been discussed based on molecular dynamics simulation. Point mutations that may improve the thermal stability of FIP-fve and FIP-bbo were predicted. These results not only present a new candidate protein for the development of anticancer adjuvants, but also provide an approach for designing FIPs with high anticancer activity.
真菌免疫调节蛋白(FIP)是具有广谱免疫调节和抗癌活性的有效小分子蛋白,可作为临床药物和保健食品添加剂开发的潜在药物。本研究通过对 Botryobasidium botryosum 基因组挖掘获得了一个新的 FIP 成员 FIP-bbo。FIP-bbo 具有 FIP 的典型特征,但与其他 FIP 在遗传上相距甚远。通过优化的大肠杆菌表达系统生产重组 FIP-bbo(rFIP-bbo),并使用 Ni-NTA 柱分离纯蛋白。抗肿瘤实验表明,FIP-bbo 在较低浓度下类似于 LZ-8 抑制各种癌细胞(Hela、Spac-1 和 A549),但其效力不如 LZ-8。基于分子动力学模拟,讨论了 FIP-bbo、FIP-fve 和 LZ-8 对癌细胞的细胞毒性的分子机制。预测了可能提高 FIP-fve 和 FIP-bbo 热稳定性的点突变。这些结果不仅为开发抗癌佐剂提供了一种新的候选蛋白,而且为设计具有高抗癌活性的 FIP 提供了一种方法。